Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
Edwards (EW) Gains From Balanced Core Growth and New Launches
by Zacks Equity Research
Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.
Top Research Reports for Alibaba, General Electric & Honeywell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), General Electric Company (GE) and Honeywell International Inc. (HON).
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics
by Zacks Equity Research
Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip
by Zacks Equity Research
Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Edwards Lifesciences (EW) Q4 Earnings Match Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 2.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System
by Zacks Equity Research
Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Stay Ahead of the Game With Edwards Lifesciences (EW) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Strength Seen in Edwards Lifesciences (EW): Can Its 6.2% Jump Turn into More Strength?
by Zacks Equity Research
Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.
ITGR vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook
by Zacks Equity Research
Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Avanos Medical (AVNS) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences (EW) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.